Synergistic Anticancer Effects of Curcumin and Hinokitiol on Gefitinib Resistant Non-Small Cell Lung Cancer Cells
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Lee, Tae-Bok | - |
dc.contributor.author | Seo, Eun-Ju | - |
dc.contributor.author | Lee, Ji-Yun | - |
dc.contributor.author | Jun, Jin Hyun | - |
dc.date.accessioned | 2021-09-02T02:28:19Z | - |
dc.date.available | 2021-09-02T02:28:19Z | - |
dc.date.created | 2021-06-19 | - |
dc.date.issued | 2018-12 | - |
dc.identifier.issn | 1934-578X | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/71347 | - |
dc.description.abstract | This study evaluated the synergistic effect of curcumin (diferuloylmethane) and hinokitiol (3-thujaplicin), natural product derived phytochemicals, on gefitinib (Iressa) resistant non-small cell lung cancer (NSCLC) cells. Gefitinib, a tyrosine kinase inhibitor targeting epidermal growth factor receptor (EGFR), is widely used for lung cancer treatment. However, gefitinib resistance is easily acquired by NSCLC and followed by the development of progressive disease. Curcumin and hinokitiol are well-known bioactive compounds demonstrating anti-inflammation, anti-bacteria and anticancer effects. However, the effects of co treatment of curcumin and hinokitiol on cancer cells have not been reported. Here, we postulated, for the first time, the possibility of combination therapy with curcumin and hinokitiol for treatment of gefitinib resistant NSCLC via increment of apoptosis and lysosomal enlargement. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | SAGE PUBLICATIONS INC | - |
dc.subject | THERAPY | - |
dc.title | Synergistic Anticancer Effects of Curcumin and Hinokitiol on Gefitinib Resistant Non-Small Cell Lung Cancer Cells | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Lee, Ji-Yun | - |
dc.identifier.scopusid | 2-s2.0-85059574262 | - |
dc.identifier.wosid | 000456230200025 | - |
dc.identifier.bibliographicCitation | NATURAL PRODUCT COMMUNICATIONS, v.13, no.12, pp.1667 - 1671 | - |
dc.relation.isPartOf | NATURAL PRODUCT COMMUNICATIONS | - |
dc.citation.title | NATURAL PRODUCT COMMUNICATIONS | - |
dc.citation.volume | 13 | - |
dc.citation.number | 12 | - |
dc.citation.startPage | 1667 | - |
dc.citation.endPage | 1671 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Pharmacology & Pharmacy | - |
dc.relation.journalResearchArea | Food Science & Technology | - |
dc.relation.journalWebOfScienceCategory | Chemistry, Medicinal | - |
dc.relation.journalWebOfScienceCategory | Food Science & Technology | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordAuthor | Synergistic effect | - |
dc.subject.keywordAuthor | Curcumin | - |
dc.subject.keywordAuthor | Hinokitiol | - |
dc.subject.keywordAuthor | Gefitinib | - |
dc.subject.keywordAuthor | Non-small cell lung cancer (NSCLC) | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.